Eliana Clark - 05 Jan 2026 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Signature
James Basta, attorney-in-fact
Issuer symbol
NTLA
Transactions as of
05 Jan 2026
Net transactions value
-$87,633
Form type
4
Filing time
07 Jan 2026, 16:03:52 UTC
Previous filing
03 Jul 2025
Next filing
03 Mar 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Clark Eliana EVP, Chief Technical Officer C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE James Basta, attorney-in-fact 07 Jan 2026 0001914448

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Sale $87,633 -9,515 -9.8% $9.21 87,118 05 Jan 2026 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.
F2 Includes 1,264 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2025.